EGFR Inhibitors

Santa Cruz Biotechnology now offers a broad range of EGFR Inhibitors. The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Upregulation of EGFR is associated with tumor progression. Abrogation of EGFR may be achieved with the use of EGFR Inhibitors with potential results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells. EGFR Inhibitors offered by Santa Cruz inhibit EGFR and, in some cases, other receptor tyrosine kinases and tumor progression related proteins. View detailed EGFR Inhibitor specifications, including EGFR Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.